Publicacións en colaboración con investigadores/as de University of Padua (16)

2024

  1. Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry

    European Journal of Pediatrics, Vol. 183, Núm. 8, pp. 3567-3578

2023

  1. Corrigendum to “Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry” [Digestive and Liver Disease Volume 55, Issue 3, March 2023, Pages 350–359] (Digestive and Liver Disease (2023) 55(3) (350–359), (S1590865822007289), (10.1016/j.dld.2022.09.020))

    Digestive and Liver Disease

  2. Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry

    Digestive and Liver Disease, Vol. 55, Núm. 3, pp. 350-359

  3. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease

    Journal of Crohn's and Colitis

  4. Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation

    Gastroenterology, Vol. 165, Núm. 4, pp. 1016-1024.e5

2022

  1. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

    Journal of Crohn's & colitis, Vol. 16, Núm. 12, pp. 1882-1892

  2. EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe

    Therapeutic Advances in Gastroenterology, Vol. 15

2021

  1. Effectiveness of third-class biologic treatment in crohn’s disease: A multi-center retrospective cohort study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  2. Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: An international multicentre study

    BMJ Open Gastroenterology, Vol. 8, Núm. 1

2020

  1. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

    The Lancet Gastroenterology and Hepatology, Vol. 5, Núm. 5, pp. 454-464

  2. The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study

    United European Gastroenterology Journal, Vol. 8, Núm. 8, pp. 949-960

2019

  1. Natural Disease Course of Ulcerative Colitis during the First Five Years of Follow-up in a European Population-based Inception Cohort - An Epi-IBD Study

    Journal of Crohn's and Colitis, Vol. 13, Núm. 2, pp. 198-208

  2. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: An Epi-IBD study

    Gut, Vol. 68, Núm. 3, pp. 423-433

2018

  1. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study

    American Journal of Gastroenterology, Vol. 113, Núm. 3, pp. 396-403

2014

  1. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: The ECCO-EpiCom cohort

    Inflammatory Bowel Diseases, Vol. 20, Núm. 1, pp. 36-46

2008

  1. Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients

    Clinical Transplantation, Vol. 22, Núm. 1, pp. 68-75